VBL Therapeutics to Report First Quarter Financial Results on May 11
May 04 2021 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT) will release its first quarter
financial results for the period ended March 31, 2021 on Tuesday,
May 11, 2021 before market open. Professor Dror Harats, M.D, Chief
Executive Officer and Amos Ron, Chief Financial Officer, will host
a conference call at 8:30am EDT the same day to discuss the results
and provide a corporate update.
Conference Call: Tuesday,
May 11, 2021 at 8:30am EDTConference ID: 13719410US: 1 877
407 9208 Israel Local: 1 809 406 247International: 1 201 493 6784
Webcast: https://edge.media-server.com/mmc/p/w794ban7
About VBLVascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for areas of unmet
need in cancer and immune/inflammatory indications. VBL has
developed three platform technologies: a gene-therapy based
technology for targeting newly formed blood vessels with focus on
cancer, an antibody-based technology targeting MOSPD2 for
anti-inflammatory and immuno-oncology applications, and the
Lecinoxoids, a family of small-molecules for immune-related
indications. VBL’s lead oncology product candidate, ofranergene
obadenovec (VB-111), is an investigational, first-in-class,
targeted anti-cancer gene-therapy agent that is being developed to
treat a wide range of solid tumors. VB-111 is currently being
studied in a VBL-sponsored Phase 3 registration enabling trial for
platinum-resistant ovarian cancer.
CONTACT:Burns McClellan
for VBL TherapeuticsLee Roth (investors) / Ryo Imai
(media)lroth@burnsmc.com / rimai@burnsmc.com+1-212-213-0006
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024